Iranian anti-cancer Herceptin to hit market June
Baku, Azerbaijan, Feb. 9
By Khalid Kazimov - Trend:
Head of the pharmaceutical Pasteur Institute of Iran Mostafa Qanei has announced that scientists at the center have managed to manufacture the anti-cancer drug Herceptin, Mehr news agency reported on Feb. 9.
Herceptin is the trade name for Trastuzumab, a monoclonal antibody that interferes with the HER2/neu receptor, and whose main use is to treat certain breast cancers.
"The drug is going to hit the market in June," he said and explained that although the drug had been unveiled by the previous Iranian administration, it took until now to be finalized, blaming the administration for a holding a hasty inaugural for the drug.
"So far the country has imported something around 600 billion rials [34,500 rials making one USD) worth of Herceptin. If we can answer the domestic demand, we would have taken a giant step," Qanei stressed.
The official also expressed happiness that the drug has already found demand from overseas and hoped that grounds would be laid for its export soon after mass production has begun.
Iranian Food and Drug Organization Director Rasoul Dinarvand announced Jan. 27 that the country's drug export has hit $150 million.
In recent years, international sanctions have made it difficult for Iran to acquire drugs from abroad. Thus, the country has tapped its domestic know-how to meet the shortage.
Iranian authorities have often said they welcome the situation as a chance for self-realization.
Qanei further explained that Herceptin has proven to be effective in treating 30 percent of the cases where it has been used.
Edited by CN